GMED Globus Medical Inc

Globus Medical reported disappointing Q3 2026 results, with global net sales falling 0.7% YoY to $763.7M, well below Wall Street expectations of approximately $ 792M. Management cut FY2026 revenue guidance to $3.09B from its previous $3.18B–$3.22B range, citing delayed U.S. Spine product launches, weaker-than-expected sales representative recruitment and continued weakness at Nevro, whose sales declined 25.7% YoY. Non-GAAP EPS of $1.23 slightly beat the $1.20 consensus, while full-year EPS guidance was maintained at $4.95–$5.05. However, the revenue shortfall and weaker growth outlook triggered negative analyst revisions. BMO Capital downgraded the stock to Market Perform from Outperform and cut its price target to $78 from $94. BTIG maintained Neutral, while Needham lowered its target to $100 from $117 but retained Buy. Wells Fargo offered a more positive view, raising its target slightly to $100 and maintaining Overweight. $GMED

$GMED Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $1.23 up 4.24% YoY • Reported revenue of $763.72M down -0.69% YoY • Globus Medical updated full-year 2026 revenue guidance to $3.09B from $3.18B to $3.22B, representing 5.1% growth, and reaffirmed non-GAAP diluted EPS guidance of $4.95 to $5.05.

$GMED 🔄 Globus Medical, Inc. announces a $500 million increase to its share repurchase program. Timely market event